Contrasting Merck & Co., Inc. (NYSE:MRK) & CervoMed (NASDAQ:CRVO)

Merck & Co., Inc. (NYSE:MRK) and CervoMed (NASDAQ:CRVO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Risk and Volatility

Merck & Co., Inc. has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Comparatively, CervoMed has a beta of -0.75, indicating that its share price is 175% less volatile than the S&P 500.

Earnings and Valuation

This table compares Merck & Co., Inc. and CervoMed”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$66.57 billion	5.39	$18.25 billion	$1.25	116.42
CervoMed	$4.01 million	12.14	-$26.97 million	($3.22)	-1.00

Merck & Co., Inc. has higher revenue and earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck & Co., Inc. and CervoMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	4.77%	16.73%	6.13%
CervoMed	N/A	-156.02%	-128.34%

Analyst Ratings

This is a breakdown of current ratings for Merck & Co., Inc. and CervoMed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0	10	17	0	2.63
CervoMed	1	1	4	1	2.71

Merck & Co., Inc. currently has a consensus target price of $151.32, indicating a potential upside of 3.98%. CervoMed has a consensus target price of $21.00, indicating a potential upside of 552.17%. Given CervoMed’s stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Merck & Co., Inc..

Insider & Institutional Ownership

76.1% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 25.2% of CervoMed shares are held by institutional investors. 0.2% of Merck & Co., Inc. shares are held by insiders. Comparatively, 35.8% of CervoMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Merck & Co., Inc. beats CervoMed on 10 of the 15 factors compared between the two stocks.

About Merck & Co., Inc.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

About CervoMed

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.